"The Bodyport Cardiac Scale is a significant step forward in the standard of care for the remote management of patients with cardiorenal conditions. By providing a longitudinal view of fluid status, care teams can more effectively manage their patients through simple, optimized lifestyle and medication adjustments," said Corey Centen, Co-Founder, President, and CTO, Bodyport.
Over 10 leading hospitals and healthcare systems across the U.S. have already participated in Bodyport's clinical studies. The company plans to roll out the technology more broadly later this year.
Ad Statistics
Times Displayed: 797
Times Visited: 5 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
About Bodyport
Based in San Francisco, Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by collecting clinically actionable biomarkers from simple, daily experiences. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient's daily life. Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital.
Based in San Francisco, the company is backed by top-tier investors such as Boehringer Ingelheim Venture Fund, Initialized Capital, Playground Global, Rock Health, and Y Combinator.
Back to HCB News
